HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J supports BASF ingredient

This article was originally published in The Rose Sheet

Executive Summary

FDA should expedite review of BASF's Time & Extent Application for UVB absorber octyl triazone, marketed in Europe as Uvinul T-150, Johnson & Johnson says in an Oct. 7 letter to the agency. While J&J "has no experience with this ingredient, we are aware of the limited choices available for sunscreen actives," company states. BASF first petitioned FDA to designate octyl triazone a Category I sunscreen ingredient in November 1996, based on foreign marketing experience (1"The Rose Sheet" Dec. 2, 1996, p. 8). The ingredient has been marketed in Europe since 1989 and in Japan since 1996. FDA barred interim marketing of OTC drugs in the U.S. in its final rule on "material time, material extent" criteria, and noted pending citizen petitions from sunscreen ingredient suppliers could be converted to TEAs for agency consideration of monograph eligibility (2"The Rose Sheet" Jan. 29, 2002, p. 8)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel